AbbVie

Yahoo Finance • yesterday

AbbVie’s CLL Breakthrough And US$380m Build Out Test Valuation

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AbbVie received FDA approval for a first in class, all oral, fixed... Full story

Yahoo Finance • 2 days ago

RBC Capital Launches AbbVie (ABBV) Coverage, Expects Shares to Outperform Amid Competitive Fears

AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts.RBC Capital Launches AbbVie (ABBV) Coverage, Expects Shares to Outperform Amid Competitive Fears On February 25, RBC Capital ana... Full story

Yahoo Finance • 2 days ago

Advanced Drug Delivery Market to Grow 10.2% Annually Through 2030

Boston, Feb. 25, 2026 (GLOBE NEWSWIRE) -- According to the latest BCC Research report, “Global Markets and Technologies for Advanced Drug Delivery Systems - Focus on Routes of Administration” is projected to grow from $299.6 billion in 2... Full story

Yahoo Finance • 2 days ago

Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie

Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development. Pharma stocks trade at about a 25% discount to their 10 year averages despite impr... Full story

Yahoo Finance • 3 days ago

How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie’s fair value estimate has been updated slightly, moving from about US$244.96 to about US$248.29 per share, which gives you... Full story

Yahoo Finance • 3 days ago

Personalized Medicine Market Competitive Landscape Report 2025: Company Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

Company Logo Personalized Medicine Market Poised for Tremendous Growth by 2033The global personalized medicine market, valued at approximately US$ 585.53 billion in 2026, is projected to soar to nearly US$ 1.00 trillion by 2033. A report... Full story

Yahoo Finance • 3 days ago

OTC Artificial Tears Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

Company Logo The OTC Artificial Tears market is projected to expand from USD 4.93 billion in 2025 to USD 7.22 billion by 2033, growing at a CAGR of 4.88%. This growth is driven by increased accessibility in public spaces, rising dry eye s... Full story

Yahoo Finance • 3 days ago

Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory

We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on RARE. Ultragenyx Pharmaceutical Inc.'s share was trading at... Full story

Yahoo Finance • 3 days ago

Travere Therapeutics, Inc. (TVTX): A Bull Case Theory

We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.'s share was trading at $30.07 a... Full story

Yahoo Finance • 3 days ago

This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income

AbbVie(NYSE: ABBV) is a large drug company with a somewhat unusual portfolio of products, spanning immunology (Skyrizi and Rinvoq) to esthetics (Botox). However, for many investors, the big draw is going to be the dividend. With a currentl... Full story

Yahoo Finance • 3 days ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

NORTH CHICAGO, Ill., Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a fireside chat at 10:10 a.m. Central Time... Full story

Yahoo Finance • 3 days ago

Hormone Replacement Therapy Market Competitive Landscape Report 2025: Top Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations and Launches, Sustainability Goals, Revenues

Company Logo The Hormone Replacement Therapy (HRT) market is poised to expand significantly from $23.58 billion in 2025 to $38.18 billion by 2033, driven by a CAGR of 6.21%. Key growth drivers include technological advancements, innovatio... Full story

Yahoo Finance • 3 days ago

AbbVie announces $380m investment in North Chicago API facilities

AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago site in Illinois, US. These facilities will integrate advanced manufacturing tech... Full story

Yahoo Finance • 3 days ago

FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL

AbbVie Inc. (NYSE:ABBV) is one of the best value stocks to buy now. On February 20, the US FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line treatment for adults with chronic lymphocytic leukemia/CLL.... Full story

Yahoo Finance • 4 days ago

Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential

AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Low Volatility Dividend Stocks to Invest in.Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential On February 20, Barclays began coverage of AbbVie Inc. (NYSE:ABB... Full story

Yahoo Finance • 4 days ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23 (Reuters) - AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing ‌facilities at its Illinois campus, expanding its domestic production capacity ‌for its neuroscience and... Full story

Yahoo Finance • 7 days ago

Barclays launches U.S. biopharma coverage with four preferred picks

Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myer... Full story

Yahoo Finance • 7 days ago

Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading

Company Logo Key market opportunities in the fill finish manufacturing sector include rising demand for cell and gene therapies, expansion in personalized medicine production, and increased outsourcing to CMOs. Growth is driven by innovat... Full story

Yahoo Finance • 7 days ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the potential of time off treatment, markin... Full story

Yahoo Finance • 8 days ago

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as... Full story